Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study

Table 3 Effectiveness and safety results

Timepoint	Baseline (n = 104)	8 weeks (n = 97)	16 weeks (n = 77)	6 months (n = 70)	12 months (n = 58)	P value1
Mayo Partial Index	6 (5-7)	2 (1-3); P < 0.0012	1 (0.5-2.5); P < 0.0012	0 (0-2.5); P < 0.0012	0 (0-1); P < 0.0012	< 0.001
CRP (mg/L)	5 (2-16)	2.2 (1.0-6.1); P = 0.0142	1.8 (1-4.2); P = 0.0242	1.7 (1-4); P = 0.0302	1 (0.2-3.3); P = 0.0042	< 0.001
Calprotectin (μg/g)	2000 (755.8-2392.5)	402.3 (94.5-2000.0); P = 0.0012	274 (76.2-1365.3); P < 0.001)2	229.5 (65.3-1066.3); P < 0.001)2	153 (21.3-569.0); P < 0.001)2	< 0.001
Clinical remission	-	59 (60.8); P < 0.0013	47 (61.0); P < 0.0013	43 (61.4); P < 0.0013	35 (60.3); P > 0.0013
Clinical-biochemical remission	-	32 (33.0); P < 0.0013	29 (37.6); P < 0.0013	27 (38.6); P < 0.0013	18 (31.0); P < 0.0013
Steroid-free remission	-	-	-	42 (60.0); P = 0.0393	33 (56.9); P = 0.2113
Clinical improvement	-	76 (77.9)	57 (80.7)	57 (80.7)	51 (87.2)
Urgency endoscopic scale	6 (3-8)	2 (0-4.8); P = 0.1183	0 (0-4); P = 0.0053	0 (0-4); P = 0.0033	0 (0-1.5); P = 0.0013	< 0.001
Treatment discontinuation		12 (11.5)	19 (18.2)	19 (18.2)	23 (22.1)

¹Friedman test for related samples for two-factor ranked variance analysis.

²Pairwise comparisons of Friedman test.

³McNemar test for related samples.

Data are presented as median (IQR) for continuous variables and n (%) for categorical variables. CRP: C-reactive protein.